Help Privacy Policy Disclaimer
  Advanced SearchBrowse




Journal Article

A polymorphic enhancer near GREM1 influences bowel cancer risk through diifferential CDX2 and TCF7L2 binding


Becker,  Martin
Language and Genetics Department, MPI for Psycholinguistics, Max Planck Society;
International Max Planck Research School for Language Sciences, MPI for Psycholinguistics, Max Planck Society;

Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)

(Publisher version), 2MB

Supplementary Material (public)
There is no public supplementary material available

Lewis, A., Freeman-Mills, L., de la Calle-Mustienes, E., Giráldez-Pérez, R. M., Davis, H., Jaeger, E., et al. (2014). A polymorphic enhancer near GREM1 influences bowel cancer risk through diifferential CDX2 and TCF7L2 binding. Cell Reports, 8(4), Pages 983-990. doi:10.1016/j.celrep.2014.07.020.

Cite as: https://hdl.handle.net/11858/00-001M-0000-0023-BFB1-F
A rare germline duplication upstream of the bone morphogenetic protein antagonist GREM1 causes a Mendelian-dominant predisposition to colorectal cancer (CRC). The underlying disease mechanism is strong, ectopic GREM1 overexpression in the intestinal epithelium. Here, we confirm that a common GREM1 polymorphism, rs16969681, is also associated with CRC susceptibility, conferring ∼20% differential risk in the general population. We hypothesized the underlying cause to be moderate differences in GREM1 expression. We showed that rs16969681 lies in a region of active chromatin with allele- and tissue-specific enhancer activity. The CRC high-risk allele was associated with stronger gene expression, and higher Grem1 mRNA levels increased the intestinal tumor burden in ApcMin mice. The intestine-specific transcription factor CDX2 and Wnt effector TCF7L2 bound near rs16969681, with significantly higher affinity for the risk allele, and CDX2 overexpression in CDX2/GREM1-negative cells caused re-expression of GREM1. rs16969681 influences CRC risk through effects on Wnt-driven GREM1 expression in colorectal tumors.